Pipeline Overview

Our portfolio of development programs targets prevalent food allergies.

Program
Pre-ind
Phase 1
Phase 2
Phase 3
Approved
Phase

PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]

Approved

PALFORZIA® POSEIDON Study

PH 3

PALFORZIA® + adjunctive dupilumab

PH 2

AR201* (EGG)

PH 2

AR401* (MULTI-TREE NUT)

PRE-IND

AIMab7195

PRE-IND

*These product candidates are based on foods that have not shown toxicology issues except in their functions as allergens; we have not been required to and at this time do not anticipate conducting Phase 1 clinical trials.